46.02

2.64% -1.25

After Hours: 45.31 -0.71 -1.54%

Kiniksa Pharmaceuticals International Plc (KNSA)

Overview News Price History Option Chain Financials Discussions Forecast

Kiniksa Pharmaceuticals International Plc stock is traded at $46.02, with a volume of 729.57K. It is down -2.64% in the last 24 hours and up +8.08% over the past month. Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Previous Close:

$47.27

Open:

$46.68

24h Volume:

729.57K

Relative Volume:

1.36

Market Cap:

$3.52B

Revenue:

$597.97M

Net Income/Loss:

$35.92M

P/E Ratio:

102.65

EPS:

0.4483

Net Cash Flow:

$101.73M

1W Performance:

+5.82%

1M Performance:

+8.08%

6M Performance:

+28.87%

1Y Performance:

+115.15%

1-Day Range:

$44.83

$46.72

1-Week Range:

$43.03

$47.46

52-Week Range:

$18.25

$49.12

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile

Name

Kiniksa Pharmaceuticals International Plc

Sector

Healthcare (1108)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

(781) 431-9100

Address

105 PICCADILLY, SECOND FLOOR, LONDON

Employee

366

Twitter

@kiniksa

Next Earnings Date

2024-10-29

Latest SEC Filings

KNSA's Discussions on Twitter

Compare KNSA vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KNSA Kiniksa Pharmaceuticals International Plc	46.02	3.62B	597.97M	35.92M	101.73M	0.4483
TAK Takeda Pharmaceutical Co Adr	17.76	57.56B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	122.23	53.17B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.33	46.62B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	31.75	38.33B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	485.06	21.48B	3.13B	1.27B	1.12B	26.39

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-19-26	Initiated	Canaccord Genuity	Buy
Sep-29-25	Initiated	TD Cowen	Buy
Mar-13-25	Initiated	Citigroup	Buy
Sep-13-24	Initiated	Jefferies	Buy
May-03-24	Initiated	Wells Fargo	Overweight
Jun-29-20	Reiterated	BofA Securities	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Mar-11-19	Initiated	Barclays	Overweight
Dec-12-18	Reiterated	Wedbush	Outperform
Jun-19-18	Initiated	JMP Securities	Mkt Outperform

View All

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News

08:22 AM

Vanguard Group Inc. Trims Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat

08:22 AM

04:12 AM

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shows Strong Growth and Bullish Chart Setup - ChartMill

04:12 AM

04:00 AM

Fisher Asset Management LLC Acquires 180,029 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat

04:00 AM

Mar 04, 2026

Kiniksa Pharmaceuticals (KNSA) CMO sells 40K shares after option exercise - Stock Titan

Mar 04, 2026

How Investors Are Reacting To Kiniksa (KNSA) Turning ARCALYST Revenue Into Full-Year Profitability And Flexibility - simplywall.st

Mar 04, 2026

Mar 03, 2026

Kiniksa Pharmaceuticals (KNSA) Stock Analysis: Robust Growth Potential With 23% Upside - DirectorsTalk Interviews

Mar 03, 2026

Mar 02, 2026

Kiniksa (NASDAQ: KNSA) Rule 144 notice: 40,000-share cashless exercise - Stock Titan

Mar 02, 2026

KNSA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 02, 2026

Feb 27, 2026

Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Prime Example of Affordable Growth (GARP) Investing - ChartMill

Feb 27, 2026

Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Volatility - Yahoo Finance

Feb 27, 2026

Feb 26, 2026

KNSA/N Stock Price and Chart — BIVA:KNSA/N - TradingView

Feb 26, 2026

Feb 25, 2026

Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference - GlobeNewswire

Feb 25, 2026

The Analyst Verdict: Kiniksa Pharmaceuticals In The Eyes Of 4 Experts - Benzinga

Feb 25, 2026

KNSA: Wells Fargo Raises Price Target and Maintains Overweight R - GuruFocus

Feb 25, 2026

KNSA: Wedbush Raises Price Target to $53, Maintains Outperform R - GuruFocus

Feb 25, 2026

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 25, 2026

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Compelling Value Investment - ChartMill

Feb 25, 2026

Kiniksa Pharmaceuticals (KNSA) Stock Analysis: A Biopharma's Strong Growth Trajectory And 17.9% Upside Potential - DirectorsTalk Interviews

Feb 25, 2026

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shares Gap Down on Disappointing Earnings - Defense World

Feb 25, 2026

Kiniksa outlines $900M–$920M 2026 ARCALYST revenue guidance as market penetration deepens - MSN

Feb 25, 2026

Beyond the Balance Sheet: What SWOT Reveals About Kiniksa Pharma - GuruFocus

Feb 25, 2026

Feb 24, 2026

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - AOL.com

Feb 24, 2026

Kiniksa (KNSA) Q4 2025 Earnings Call Transcript - The Globe and Mail

Feb 24, 2026

Kiniksa Pharmaceuticals International, plcClass A Ordinary Shares (NQ: KNSA - The Chronicle-Journal

Feb 24, 2026